AtriCure
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2000-11-01
- Employees
- 1.2K
- Market Cap
- -
- Website
- http://www.atricure.com
- Introduction
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.
Watchman FLX Superior to Anticoagulants for Stroke Risk Reduction Post-Cardiac Ablation
• The OPTION trial demonstrated that Boston Scientific's Watchman FLX is superior to oral anticoagulation (OAC) in reducing bleeding events in patients post-cardiac ablation.
• The study met its primary safety endpoint, showing Watchman FLX had significantly lower rates of major bleeding compared to OAC at 36 months.
• Watchman FLX showed non-inferiority to OAC for the primary efficacy endpoint of all-cause death, stroke, or systemic embolism.
• The findings suggest Watchman FLX could become a frontline therapy for stroke risk reduction in atrial fibrillation patients undergoing cardiac ablation.
AtriCure's EPi-Sense System Receives FDA Approval for Long-Standing Persistent Afib Treatment
• AtriCure's EPi-Sense system has gained FDA approval for treating long-standing persistent atrial fibrillation (Afib), offering a new option for a challenging patient population.
• The Converge clinical trial demonstrated the superiority of Hybrid AF therapy using the EPi-Sense system compared to endocardial catheter ablation alone.
• Hybrid AF therapy showed a 29% absolute improvement in efficacy at 12 months and a 35% absolute improvement at 18 months compared to catheter ablation.
• The EPi-Sense system improves electrophysiology lab efficiency by reducing endocardial ablation times by over 40 minutes, enhancing patient throughput.
© Copyright 2025. All Rights Reserved by MedPath